Blog - Page 3 of 5734 - QualityStocks

ThursdaySep 10, 2026 11:15 am

SS Innovations International Inc. (NASDAQ: SSII) Brings Robotic Cardiac Surgery to Sri Lanka

The company has supported the launch of Sri Lanka’s first robotic cardiac surgery program at Kings Hospital Colombo using the SSi Mantra 3.0 surgical robotic system. The program began with a robotic-assisted LIMA takedown, performed by SS Innovations founder and Chairman Dr. Sudhir Srivastava alongside Kings Hospital cardiothoracic surgeon Dr. Rajitha DeSilva. Kings Hospital has completed more than 25 robotic procedures in three weeks, according to a recent company video describing the program’s early activity. SS Innovations reported 224 cumulative SSi Mantra installations across 12 countries at the end of the second quarter. The company’s second-quarter revenue reached $13.9 million,…

ThursdaySep 10, 2026 10:30 am

Wrap Technologies Inc. (NASDAQ: WRAP) Broadens Public Safety Platform as Training, Technology and Response Capabilities Converge

WRAP(R) is expanding beyond individual public safety technologies by integrating training, situational awareness, response capabilities, and continuous learning into a broader platform. Its relationship with WOFT Charities and Florida’s Teacher Safety Training Program demonstrates how WRAP’s training methodology can extend into new professional environments. The company’s Wrap Tactics(TM) learning management system could provide a scalable foundation for certification, recurring training, and broader adoption across education, private security, military, and other markets. Public safety technology is increasingly moving beyond individual products as organizations seek solutions that combine technology with training, situational awareness, real-world scenarios, and continuous professional development. Wrap Technologies (NASDAQ:…

ThursdaySep 10, 2026 10:20 am

QualityStocksNewsBreaks – Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) Plans Phase 2 Psilocybin Trial for Major Depressive Disorder

This article has been disseminated on behalf of Optimi Health Corp. and may include paid advertising. Optimi Health (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) plans to initiate a multisite Phase 2 clinical trial evaluating psilocybin-assisted therapy for major depressive disorder (“MDD”) in the first half of 2027, with dosing expected to be completed by year-end. The Health Canada-authorized trial will enroll up to 200 participants across multiple Canadian sites and evaluate the safety and efficacy of a single supervised dose of Optimi naturally derived psilocybin, manufactured at its GMP facility. The company will exclusively own the trial results and plans…

ThursdaySep 10, 2026 10:10 am

QualityStocksNewsBreaks – SPARC AI Inc. (CSE: SPAI) (OTCQB: SPAIF) (Frankfurt: 5OV0) Launches Overwatch Patrol for GPS-Denied Dismounted Operations

This article has been disseminated on behalf of SPARC AI Inc. and may include paid advertising. SPARC AI (CSE: SPAI) (OTCQB: SPAIF) (Frankfurt: 5OV0) launched Overwatch Patrol, a dismounted positioning application designed to provide continuous location information to soldiers and security personnel when GPS is jammed, spoofed, degraded or unavailable. Unveiled at the International Defense Industry Exhibition (“MSPO”) in Kielce, Poland, Overwatch Patrol operates through the company’s cloud-based Overwatch Positioning Network without additional hardware and can be delivered through a native application or standard web browser. The platform enables multiple team members to share live positions without GPS and allows…

ThursdaySep 10, 2026 10:00 am

QualityStocksNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Advances Lucid-MS Toward Phase 2 Trial Following FDA Clearance

This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising. Quantum BioPharma (NASDAQ: QNTM) is advancing Lucid-MS toward a randomized, double-blind, placebo-controlled phase 2 trial in multiple sclerosis (“MS”) following U.S. Food and Drug Administration (“FDA”) clearance of its Investigational New Drug (“IND”) application. Lucid-MS is a patented, first-in-class, non-covalent inhibitor of peptidyl arginine deiminase 2 (“PAD2”) designed to target demyelination directly rather than suppress the immune system. The editorial also highlights Quantum BioPharma research collaboration with Massachusetts General Hospital and Harvard Medical School involving the [¹⁸F]3F4AP PET imaging tracer, which is being evaluated as a…

ThursdaySep 10, 2026 9:52 am

QualityStocksNewsBreaks – American Fusion Inc. (OTC: AMFN) Highlights Texatron(TM) Fusion Engine(TM) Development, AI Power Strategy in New Interview

American Fusion (OTC: AMFN) announced the release of a new AGORACOM interview featuring Executive Chairman Brent Nelson discussing development of the company proprietary Texatron(TM) Fusion Engine(TM) and its strategy for addressing growing electricity demand from artificial intelligence, data centers and other power-intensive applications. Nelson discusses the company 5 MW preproduction Texatron(TM), plans for 10 MW and 20 MW systems and Texas authorization to test 12 planned system sizes ranging from approximately 500 kW to 1 GW, while noting the ratings are intended system sizes and not demonstrated electrical output. American Fusion is targeting documented test results demonstrating the Texatron(TM) can generate and capture sufficient energy for conversion into usable electricity, with…

ThursdaySep 10, 2026 9:50 am

QualityStocksNewsBreaks – SS Innovations International, Inc. (NASDAQ: SSII) Reports 79% Growth in SSi Mantra Procedures, Expands Global Reach

SS Innovations International (NASDAQ: SSII) provided an update on the continued expansion and utilization of its SSi Mantra surgical robotic system, reporting 14,103 cumulative procedures as of Sept. 8, 2026, up 79% from 7,885 at year-end 2025, while its installed base increased 42% to 238 systems from 168. The SSi Mantra is now installed across 12 countries, approximately 1,500 physicians have been trained on the platform and the system has been used for more than 170 types of surgical procedures. Recent international milestones include the launch of robotic cardiac surgery in Colombia, installation of the first SSi Mantra in Sri…

ThursdaySep 10, 2026 9:45 am

Nightfood Holdings (NGTF) Expands AI Robotics Strategy as Labor Shortages Accelerate Automation Demand

TechForce Robotics uses AI-enhanced automation to help businesses address labor shortages, rising costs and operational inefficiencies. Its Robotics-as-a-Service Provider (“RaaSP”) model lowers barriers to adoption while creating potential recurring revenue opportunities. A potential deployment of up to 5,000 robotic systems with NBR Intelligence signals TechForce’s growing ambitions in industrial and factory automation. Nightfood Holdings (OTCQB: NGTF), doing business as TechForce Robotics, is positioning itself among the several trends reshaping the global economy: persistent labor shortages, rising operating costs and accelerating adoption of AI-enhanced automation. Global industrial robot installations reached 542,000 units in 2024, more than double the figure recorded a…

ThursdaySep 10, 2026 9:36 am

QualityStocksNewsBreaks – SuperQ Quantum Computing Inc. (CSE: QBTQ) (OTCQB: QBTQF) (FSE: 25X) Advances Super Nova(TM) Modular Hybrid Quantum Computer

This article has been disseminated on behalf of SuperQ Quantum Computing Inc. and may include paid advertising. SuperQ Quantum (CSE: QBTQ) (OTCQB: QBTQF) (FSE: 25X) is actively developing its flagship Super Nova(TM) modular hybrid quantum computer, with the quantum hardware layer being developed at the University of Waterloo Digital Quantum Matter Lab under the supervision of superconducting quantum physics expert Professor Matteo Mariantoni. Designed to integrate with enterprise IT and high-performance computing infrastructure, Super Nova(TM) combines quantum hardware with classical CPUs and GPUs to address cost, operating-system and interoperability barriers to broader quantum computing adoption. SuperQ is also expanding its Waterloo technical team through the recruitment of multiple quantum hardware scientists focused…

ThursdaySep 10, 2026 9:10 am

QualityStocksNewsBreaks – Onco-Innovations Limited (CBOE CA: ONCO)(OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) CMO Discusses ONC010, Novel PNKP Target in BioMedWire Podcast

This article has been disseminated on behalf of Onco-Innovations Limited and may include paid advertising. Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) Chief Medical Officer Dr. Islam Mohamed joined IBN BioMedWire Podcast to discuss lead drug candidate ONC010, the company novel approach to targeting the DNA repair enzyme polynucleotide kinase phosphatase (“PNKP”) and its planned first-in-human clinical program. Mohamed highlighted ONC010 two selectivity mechanisms — synthetic lethality designed to limit drug lethality to cancer cells that have lost PTEN or SHP-1 and nanoparticle delivery intended to concentrate the drug within tumor tissue — as well as preclinical…

Site Search

Company Search